Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematologic Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD123/IL3RA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD123/IL3RA ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed (native glycosylation). | View CD123/IL3RA Products |
| Gene Delivery | CD123/IL3RA Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View CD123/IL3RA Products |
| Benchmark Ab | Anti-CD123 (Sequence representative of Tagraxofusp, Pivekimab, and 7G3/CSL362 lineage). Recombinant positive control for binding/blocking/internalization assays. | View CD123/IL3RA Products |
| Validator | CD123/IL3RA siRNA Set. For knockdown verification and specificity controls. | View CD123/IL3RA Products |
| Beta Subunit | CD131/IL3RB Protein. Common beta subunit for functional heterodimer assays. | View CD131 Products |
| Synergistic Target A | FLT3. Co-targeting strategy in AML blasts. | View FLT3 Products |
| Synergistic Target B | CD33. Synergistic target for dual-targeting in AML. | View CD33 Products |
| Synergistic Target C | CD47. Macrophage checkpoint bypass for enhanced phagocytosis. | View CD47 Products |
| Lineage Marker | CD45 (PTPRC). Pan-leukocyte reference for AML targeting. | View CD45 Products |
| Related Target | CSF2RA (GM-CSFR Alpha). Cross-screening to rule out cytokine receptor off-target effects. | View CSF2RA Products |
| Related Target | KIT (CD117). Co-expressed on hematopoietic progenitors; compensatory signaling node in AML resistance. | View KIT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation (Toxicology bridging) | Human/Cyno/Mouse CD123 ortholog proteins available with >95% purity; mass spec verified sequence identity. |
| Internalization efficiency screening (ADC/PDC requirement) | ECD-Fc retains ligand-binding pocket; Lentivirus generates high-density surface expression cell lines for quantitative flow cytometry and endocytosis tracking. |
| Heterodimer functional validation (IL3 signaling) | CD131 (beta chain) co-expression systems available; pair for dimerization assays and signaling blockade studies. |
| Specificity vs IL5RA and CSF2RA (off-target liability) | Sequence-verified IL5RA and CSF2RA proteins available for cross-binding ELISA/SPR panels; homologous receptor family panel for subfamily selectivity. |
| Lack of Controls | Clinical Benchmark Antibodies (Tagraxofusp, Pivekimab, 7G3-class sequences) included. |
| False Positives | Validated siRNA included for specificity checks and target knockdown confirmation. |
Live CD123/IL3RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD123 therapeutics is intensifying, with major players shifting focus from first-generation toxin conjugates (e.g., Tagraxofusp) to next-generation ADCs, bispecific engagers, and cell therapies. As Stemline/Pfizer's Tagraxofusp established clinical proof-of-concept in BPDCN, the competitive landscape is rapidly expanding into AML and MDS indications where CD123 expression defines leukemic stem cell populations. However, early-phase setbacks due to on-target hematologic toxicity and capillary leak syndrome (CLS) have underscored the need for differentiated epitopes, pH-dependent binding, and low-affinity engineering to spare normal hematopoietic stem cells and endothelial cells. The next wave of R&D is targeting dual-antigen strategies combining CD123 with FLT3, CD33, or CD45 to minimize off-tumor toxicity while maintaining potency against blast populations. Additionally, antibody engineering efforts are optimizing for pH-dependent binding release to enhance internalization efficiency—a critical parameter for payload delivery. Masked antibodies, logic-gated bispecifics, and combination regimens with hypomethylating agents are emerging as key strategies to improve therapeutic index.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | ImmunoGen/AbbVie, CSL Behring, NovelMed, Stemline/Menarini | AML, BPDCN | Internalization assay (Need high-purity ECD-Fc with native glycosylation and full-length stable cell lines) |
| Immunotoxin (Targeted Cytotoxin) | Pfizer/Stemline (Tagraxofusp), Menarini | BPDCN (Approved), AML | Binding affinity vs cyno (Toxicology bridging) and selectivity assay (Need WT and ortholog proteins) |
| Bispecific T-cell Engager | AbbVie, Sanofi, Xencor, MacroGenics | Relapsed/Refractory AML | Heterodimer validation and cytokine release minimization (Need cross-reactive species controls and low-affinity variants) |
| Monoclonal Antibody | CSL Behring/AstraZeneca (CSL362/7G3) | AML | Blocking vs. non-blocking epitope mapping (Need WT and isoform proteins) |
| CAR-T / Cell Therapy | Cellectis, Cartesian, Mustang Bio | R/R AML, BPDCN | ScFv specificity and cross-reactivity panel (Need Human/Cyno/Mouse orthologs and lentivirus-stable target cell lines) |